(VIANEWS) – Safe Bulkers (SB), First Busey Corporation (BUSE), Universal Health Services (UHS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Safe Bulkers (SB)
12.9% sales growth and 10.69% return on equity
Safe Bulkers, Inc., together with its subsidiaries, provides marine drybulk transportation services. It owns and operates drybulk vessels for transporting bulk cargoes primarily coal, grain, and iron ore. The company has a fleet of 47 drybulk vessels having an aggregate carrying capacity of 4,719,600 deadweight tons. Its fleet consists of 10 Panamax class vessels, 11 Kamsarmax class vessels, 18 post-Panamax class vessels, and 8 Capesize class vessels. Safe Bulkers, Inc. was incorporated in 2007 and is based in Monaco.
Earnings Per Share
As for profitability, Safe Bulkers has a trailing twelve months EPS of $0.67.
PE Ratio
Safe Bulkers has a trailing twelve months price to earnings ratio of 8.48. Meaning, the purchaser of the share is investing $8.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.69%.
Sales Growth
Safe Bulkers’s sales growth is 9.3% for the present quarter and 12.9% for the next.
Yearly Top and Bottom Value
Safe Bulkers’s stock is valued at $5.68 at 01:22 EST, way below its 52-week high of $6.33 and way higher than its 52-week low of $2.97.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 16, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 3.49%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 299.22M for the twelve trailing months.
2. First Busey Corporation (BUSE)
11.2% sales growth and 9.03% return on equity
First Busey Corporation operates as the bank holding company for Busey Bank that provides retail and commercial banking products and services to individual, corporate, institutional, and governmental customers in the United States. The company operates through three segments: Banking, FirsTech, and Wealth Management. It offers banking services to individual and corporate customers. The company also provides asset management, investment, brokerage, fiduciary, philanthropic advisory, tax preparation, and farm management services. Further, it offers payment technology solutions through its payment platform, such as walk-in payment processing for customers at retail pay agents; online bill payment solutions; customer service payments accepted over the telephone; mobile bill pay; direct debit services; electronic concentration of payments delivered to automated clearing house network; money management and credit card networks; and lockbox remittance processing to make payments by mail, as well as provides tools related to billing, reconciliation, bill reminders, and treasury services. The company has 46 banking centers in Illinois; 8 in Missouri; 3 in southwest Florida; and 1 in Indianapolis, Indiana. First Busey Corporation was founded in 1868 and is headquartered in Champaign, Illinois.
Earnings Per Share
As for profitability, First Busey Corporation has a trailing twelve months EPS of $1.99.
PE Ratio
First Busey Corporation has a trailing twelve months price to earnings ratio of 11.29. Meaning, the purchaser of the share is investing $11.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.03%.
3. Universal Health Services (UHS)
9.7% sales growth and 13.31% return on equity
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. It also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $11.77.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 16.16. Meaning, the purchaser of the share is investing $16.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.31%.
4. Incyte Corporation (INCY)
9.1% sales growth and 15.13% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.13%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 10.1% and 8.2%, respectively.
Volume
Today’s last reported volume for Incyte Corporation is 683729 which is 59.07% below its average volume of 1670830.
Sales Growth
Incyte Corporation’s sales growth is 5.8% for the current quarter and 9.1% for the next.
5. Grifols, S.A. (GRFS)
8.1% sales growth and 3.48% return on equity
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Earnings Per Share
As for profitability, Grifols, S.A. has a trailing twelve months EPS of $0.1.
PE Ratio
Grifols, S.A. has a trailing twelve months price to earnings ratio of 70. Meaning, the purchaser of the share is investing $70 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
